Cited by 337Cancer-related Molecular PathwaysPI3K/AKT/mTOR signaling in cancerUbiquitin and proteasome pathways

The DOI matches its Crossref record; 160 of the 175 references it cites were found in a registry or an index.

p21 in Cancer Research

Open access

Abstract

p21 functions as a cell cycle inhibitor and anti-proliferative effector in normal cells, and is dysregulated in some cancers. Earlier observations on p21 knockout models emphasized the role of this protein in cell cycle arrest under the p53 transcription factor activity. Although tumor-suppressor function of p21 is the most studied aspect of this protein in cancer, the role of p21 in phenotypic plasticity and its oncogenic/anti-apoptotic function, depending on p21 subcellular localization and p53 status, have been under scrutiny recently. Basic science and translational studies use precision gene editing to manipulate p21 itself, and proteins that interact with it; these studies have led to regulatory/functional/drug sensitivity discoveries as well as therapeutic approaches in cancer field. In this review, we will focus on targeting p21 in cancer research and its potential in providing novel therapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cancers11081178

Cites

160 of 160 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 p21 expression induction through PI3K-Akt and c-Myc pathways. In this figure, drugs are shown in green boxes and differentially expressed genes/miRNAs are shown in pink boxes. These differentially expressed genes/miRNAs and drugs positively regulate p21 expression through reducing Akt phosphorylation, inhibiting MDM2-p53 interaction, suppressing c-Myc expression, preventing p21 ubiquitylation, preventing p21 mRNA destabilization, blocking negative regulation of p21 protein, or suppressing histone deacetylation. As a conclusion, increased p21 expression induces cell cycle arrest and decreases cell viability. PI3K: Phosphoinositide 3-Kinase, Akt: Protein kinase B, ARHGAP15: Rho GTPase-Activating Protein 15, ARHGAP17: Rho GTPase Activating Protein 17, c-MYC: cellular Myelocytomatosis Oncogene, CMTM5: CKLF (Chemokine Like Factor) Like MARVEL Transmembrane Domain Containing 5, FBXO22: F-box Only Protein 22, FXR1: Fragile X-related Protein 1, GSTP1: Glutathione S-Transferase Pi 1, HDAC: Histone Deacetylase, hnRNP A2/B1: Heterogeneous Nuclear Ribonucleoprotein A2/B1, IL-6: Interleukin 6, LRH-1: Nuclear Receptor Liver Receptor Homolog-1, MAPKAPK5-AS1: MAPKAPK5 Antisense RNA 1, MDM2: Mouse Double Minute 2, mTOR: Mammalian Target of Rapamycin, PI3K: Phosphoinositide-3-Kinase, PSMD2: 26S Proteasome non-ATPase Regulatory Subunit 2, UBR5: Ubiquitin Protein Ligase E3 Component N-Recognin 5.
Figure 1 p21 expression induction through PI3K-Akt and c-Myc pathways. In this figure, drugs are shown in green boxes and differentially expressed genes/miRNAs are shown in pink boxes. These differentially expressed genes/miRNAs and drugs positively regulate p21 expression through reducing Akt phosphorylation, inhibiting MDM2-p53 interaction, suppressing c-Myc expression, preventing p21 ubiquitylation, preventing p21 mRNA destabilization, blocking negative regulation of p21 protein, or suppressing histone deacetylation. As a conclusion, increased p21 expression induces cell cycle arrest and decreases cell viability. PI3K: Phosphoinositide 3-Kinase, Akt: Protein kinase B, ARHGAP15: Rho GTPase-Activating Protein 15, ARHGAP17: Rho GTPase Activating Protein 17, c-MYC: cellular Myelocytomatosis Oncogene, CMTM5: CKLF (Chemokine Like Factor) Like MARVEL Transmembrane Domain Containing 5, FBXO22: F-box Only Protein 22, FXR1: Fragile X-related Protein 1, GSTP1: Glutathione S-Transferase Pi 1, HDAC: Histone Deacetylase, hnRNP A2/B1: Heterogeneous Nuclear Ribonucleoprotein A2/B1, IL-6: Interleukin 6, LRH-1: Nuclear Receptor Liver Receptor Homolog-1, MAPKAPK5-AS1: MAPKAPK5 Antisense RNA 1, MDM2: Mouse Double Minute 2, mTOR: Mammalian Target of Rapamycin, PI3K: Phosphoinositide-3-Kinase, PSMD2: 26S Proteasome non-ATPase Regulatory Subunit 2, UBR5: Ubiquitin Protein Ligase E3 Component N-Recognin 5.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 175 references

Cited by

Sorted by citations

Metadata

Authors
Shamloo, B., & Usluer, S.
Affiliations
  • University of Utah (US)
  • Medical University of Graz (AT)
Corresponding author
Shamloo, Bahar
Venue
Cancers
Publisher
MDPI AG
Published
2019-08-14
Volume
11
Issue
8
Pages
1178
ISSN
2072-6694 (ISSN-L)
OpenAlex
W2968190332
Cited by
336
References
175
Citations by year
2026: 18 · 2025: 47 · 2024: 63 · 2023: 65 · 2022: 52 · 2021: 56 · 2020: 31 · 2019: 3
FWCI
3.41
Type
journal article
Language
en
Open access
Locations
  • Cancers (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
Keywords
p21, cell cycle inhibitors, p53, tumor suppression, phenotypic plasticity, oncogenic function, anti-apoptotic effects, subcellular localization, genome editing, cancer therapy, drug sensitivity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review